X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The Company intends to use the net proceeds to fund research and development of its clinical-stage product candidate, VX-745 (neflamapimod), an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha.
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: VX-745
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $149.4 million Upfront Cash: $50.0 million
Deal Type: Private Placement March 28, 2024
Details:
The Combined company will pursue late-stage clinical development of oral VX-745 (neflamapimod), a small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a), for the treatment of dementia with Lewy bodies.
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: VX-745
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EIP Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 16, 2023
Details:
VX-745 (neflamapimod) is an investigational drug that is an orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, which is investigated for the treatment of dementia with lewy bodies.
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: VX-745
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
The Combined company will pursue late-stage clinical development of oral neflamapimod, a small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a), for the treatment of dementia with Lewy bodies.
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: VX-745
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CervoMed
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Merger March 30, 2023
Details:
VX-745 (neflamapimod) is an investigational oral, brain-penetrating small molecule drug. The combined pre-clinical and clinical data are consistent with neflamapimod treating the underlying disease process and having the potential to be the first disease-modifying treatment.
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: VX-745
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
Neflamapimod (VX-745) is an investigational oral, brain-penetrating small molecule drug that inhibits the intra-cellular enzyme p38MAP kinase alpha (p38α which is expressed in neurons under conditions of stress and disease.
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: VX-745
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Results of AscenD-LB Phase 2 clinical study demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB).
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Patients receiving neflamapimod three times daily demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily.
Lead Product(s): Neflamapimod
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
